Limited polymorphism in Plasmodium falciparum ookinete surface antigen, von Willebrand factor A domain-related protein from clinical isolates by Richards, Jack S et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Malaria Journal
Open Access Research
Limited polymorphism in Plasmodium falciparum ookinete surface 
antigen, von Willebrand factor A domain-related protein from 
clinical isolates
Jack S Richards*1, Nicholas J MacDonald2 and Damon P Eisen1
Address: 1Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Grattan St, Parkville, Victoria, 3050, Australia and 
2Malaria Vaccine Development Branch, NIAID, National Institutes of Health, Rockville, Maryland, USA
Email: Jack S Richards* - richards@wehi.edu.au; Nicholas J MacDonald - nmacdonald@niaid.nih.gov; 
Damon P Eisen - damon.eisen@mh.org.au
* Corresponding author    
Abstract
Background: As malaria becomes increasingly drug resistant and more costly to treat, there is
increasing urgency to develop effective vaccines. In comparison to other stages of the malaria
lifecycle, sexual stage antigens are under less immune selection pressure and hence are likely to
have limited antigenic diversity.
Methods: Clinical isolates from a wide range of geographical regions were collected. Direct
sequencing of PCR products was then used to determine the extent of polymorphisms for the
novel Plasmodium falciparum sexual stage antigen von Willebrand Factor A domain-related Protein
(PfWARP). These isolates were also used to confirm the extent of diversity of sexual stage antigen
Pfs28.
Results: PfWARP was shown to have non-synonymous substitutions at 3 positions and Pfs28 was
confirmed to have a single non-synonymous substitution as previously described.
Conclusion:  This study demonstrates the limited antigenic diversity of two prospective P.
falciparum sexual stage antigens, PfWARP and Pfs28. This provides further encouragement for the
proceeding with vaccine trials based on these antigens.
Background
Development of effective Plasmodium falciparum vaccines
is a global health priority with all stages of the malaria life-
cycle being investigated for possible vaccine strategies [1].
Mosquito-stage vaccines aim to induce immunity to the
forms of the parasite found in the mid-gut of mosquitoes:
the sexual stage macro- and microgametes and the post-
fertilization zygotes and ookinetes. Antibodies that target
antigens in these stages prevent infection in the mosquito
thus breaking the transmission cycle. Since malaria trans-
mission is both highly localized and focal [2], such vac-
cines may form a useful element as part of integrated
control programmes to locally eliminate or substantially
reduce transmission. They may also have a useful role in
conjunction with chemotherapeutic agents to prevent
drug-resistant or vaccine-escape mutants.
The P. falciparum, mosquito-stage vaccine candidate anti-
gens include Pfs25, Pfs28, Pfs48/45, Pfs230 and the
recently described, von Willebrand factor A domain-
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related protein (PfWARP) [3,4]. PfWARP (PF08_0136b) is
located on chromosome 8 (GenBank: NC_004329
Region: 1221207...1222079) and encodes a 290 amino
acid protein. On the basis of previous study of ortho-
logues in Plasmodium berghei and Plasmodium gallinaceum,
PfWARP is thought to be a soluble micronemal protein
expressed in the late ookinete and early oocyst [5-7]. It is
proposed that the von Willebrand factor A domains found
in PfWARP and other malaria antigens, including circum-
sporozoite protein and thrombospondin-related anony-
mous protein have a role as an adhesive substrate and
may assist in host cell invasion [7,8].
Pfs28 (PF10_0302) is a lead candidate for a transmission-
blocking vaccine. It is a 28-kDa protein and is presumably
anchored to parasite surface by glycosylphosphatidyli-
nositol [9]. It is encoded on chromosome 10 and shares
putative functional determinants with Pfs25. Pfs28 is
expressed on the surface of late ookinetes of P. falciparum
and it is proposed that it is involved in adherence to the
mosquito's gut epithelium [10]. Previous studies have
examined Pfs28 polymorphism in laboratory isolates
Dd2, 2D11, CAMP, LE5, LF4, HB3, 7G8 [11] and from 32
field isolates from a geographically restricted region in the
Philippines [12]. These have shown the presence of a sin-
gle non-synonymous A274G base substitution, resulting
in a conservative amino acid change from lysine to
arginine (GenBank: L25843).
As part of the assessment of PfWARP's suitability as a vac-
cine candidate, the diversity in this gene was assessed
using  P. falciparum field isolates from a range of geo-
graphic locations. In addition, Pfs28 was sequenced in the
same isolates to extend previous observations of its' diver-
sity.
Methods
Review and approval of the study was obtained from the
Research Ethics Committee of the Royal Brisbane Hospi-
tal and the Melbourne Health Human Research Ethics
Committee. Clinical samples from P. falciparum-infected
patients were obtained from the Malaria Reference Labo-
ratory at the Royal Brisbane Hospital, Queensland.
Twenty-two samples were studied from unrelated travel-
lers returning from Papua New Guinea, Solomon Islands,
Pakistan, Kenya, Tanzania, Uganda, Zimbabwe, and
Ghana.
Whole blood specimens were stored in 8 M guanidine
hydrochloride/0.1 M Na H2PO4. Genomic DNA was iso-
lated from the samples using the QIAquick® PCR purifica-
tion kit (Qiagen, Hilden, Germany). PfWARP and Pfs28
polymorphism was assessed using PCR conditions as out-
lined (Table 1). All PCR reactions used Amplitaq Gold®
DNA polymerase (Roche Diagnostics, Mannheim, Ger-
many). PCR products were detected after submarine elec-
trophoresis using 1% agarose gel stained with ethidium
bromide. PCR products were purified for direct sequenc-
ing using QIAquick® PCR purification kit (Qiagen, Hilden,
Germany) or were agarose gel purified using MinElute Gel
extraction kit® (Qiagen, Hilden, Germany) purification
kit. DNA sequencing was performed utilising the auto-
mated 3100 Genetic Analyser capillary system. In addi-
tion, samples with multiple infections of P. falciparum
Table 1: Details of primers, primer and MgCl2 concentrations and cycle conditions for the amplification of PfWARP and Pfs28 genes. 
Oligonucleotide positions are based on NCBI Genebank sequence PfWARP (NC_004329) and Pfs28 (L25843).
Oligonucleotide Nucleotide sequence Description Primer (μM)/MgCl2 (mM) Cycle conditions
PfWARP_USF GTTGTTGTATAATAAGAG
AGAGAAAAATG
WARP bases 1221181 to 
1221209
0.6/2.0 94°C 10 min (94°C 30 sec, 
52°C 30 sec, 72°C 60 sec) 40 
cycles, 72°C 5 min
PfWARP_IR TACATCTTATGATTTATT
CTTATCACATA
WARP bases 1222057 to 
1222085
PfWARP_IF GTGGTATTATGTTTGGGT
ATGATATCAGC
WARP bases 1221222 to 
1221250
0.6/1.5 94°C 10 min (94°C 30 sec, 
52°C 30 sec, 72°C 60 sec) 25 
cycles, 72°C 5 min
PfWARP_IR TACATCTTATGATTTATT
CTTATCACATA
WARP bases 1222057 to 
1222085
Pfs28_F1 ATGAATACATATTTTAAG
GTACTTCTT
Pfs28 bases 60 to 86 1.0/2.5 94°C 10 min (94°C 60 sec, 
46°C 60 sec, 72°C 45 sec) 40 
cycles, 72°C 10 min
Pfs28_R650 GAGCATACAATCAGAAC
GTGTGTTAGG
Pfs28 bases 680 to 709
Pfs28_F40 CAACTTTACATAACGTTG
AATAAGGCTC
Pfs28 bases 99 to 126 1.0/2.5 94°C 10 min (94°C 60 sec, 
50°C 60 sec, 72°C 45 sec) 34 
cycles, 72°C 10 min
Pfs28_R630 GCATACAATCAGAACGT
GTGTTAG
Pfs28 bases 666 to 689Malaria Journal 2006, 5:55 http://www.malariajournal.com/content/5/1/55
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were detected by merozoite surface protein 2 (MSP2) PCR
as previously described [13]. Amplification of this highly
polymorphic gene allowed rapid detection of size separa-
ble fragments by gel electrophoresis.
Results
PfWARP was amplified from 19 of the field samples and
three laboratory strains (3D7, FC27, and FCR3). As
judged by MSP2 genotyping, there were multiple infec-
tions in 7 of the 19 patient samples. These 7 patient sam-
ples had a minimum of 26 genetically different clones of
P. falciparum. However, direct sequencing of PCR products
from each of these samples showed only a single genotype
of PfWARP with no mixed peaks in the sequencing traces.
Non-synonymous nucleotide substitutions were found to
occur in three positions amongst the variant sequences.
No synonymous substitutions were identified. The pre-
dicted amino acid changes were conservative and con-
tained within the single Von Willebrand factor domain
(Table 2). Sample numbers were insufficient to determine
whether there was any geographic distribution to the
PfWARP alleles.
Pfs28 was amplified in 22 field samples (representing at
least 31 clones due to the existence of multiple MSP2 alle-
les in nine patients) and in 3D7. The A274G, non-synon-
ymous, nucleotide substitution as previously described,
was found with 11 of the 22 samples having the A274
allele (Table 2). No other nucleotide substitutions were
present. This data was combined with that from Hafalla et
al [12] to consider the geographic distribution of Pfs28
alleles. In Asia/Pacific isolates, 42 of 48 carried the G274
allele while only 1 of 14 of Africa/Americas isolates bore
this allele (p < 0.001, Fisher's exact test). While recogniz-
ing the size limitations of this study, it is still striking that
there is such a significant difference in the geographic dis-
tribution of these Pfs28 alleles (Table 2).
Discussion
For the first time, this study addresses the issue of anti-
genic diversity in PfWARP. This antigen appears to have
restricted diversity with infrequent point mutations as
defined. Additionally, by documenting the genotype of
Pfs28 in field isolates from a larger cohort with wider geo-
graphic distribution than in previous studies, we confirm
that there are only two alleles of this protein. Restricted
antigenic diversity has been described in other sexual
stage antigens and is explicable due to the absence of
human immune selection pressure [14-16]. By contrast,
asexual stage candidate antigens such as MSP2 are highly
polymorphic due to P. falciparum's immune evasion
mechanisms [17].
Pfs28, and its orthologues from other species, Pvs28 (Plas-
modium vivax) and Pbs21 (P. berghei) clearly induce anti-
bodies that block parasitic infection in mosquitoes and
are thus candidate antigens for inducing transmission
blocking immunity in humans either alone [18] or in
combination with other mosquito-stage antigens. So far
there have been two published vaccine trials in humans
with Pfs25 [19] and with its P. vivax orthologue, Pvs25
[20], with other trials currently underway.
Conclusion
The demonstration of limited sequence variation in the
newly described P. falciparum ookinete surface antigen
PfWARP and the confirmed highly conserved nature of
Pfs28 in clinical samples from a wide geographical distri-
bution, increase the confidence that these proteins may
also be suited for mosquito-stage vaccine development.
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